Sanofi has appointed Bill Sibold as executive vice president for Sanofi Genzyme in a move that will also see he join the company’s executive committee.
Previously head of Sanofi Genzyme’s multiple sclerosis, oncology and immunology organisation, Sibold has experience in leading global therapy launches.
Prior to Sanofi, Sibold has held a number of leadership positions for biopharmaceutical companies such as Biogen, Avanir Pharmaceuticals and Eli Lilly.
Oliver Brandicourt, chief executive officer at Sanofi, said: “With a strong commitment to serving patients, Sanofi Genzyme has evolved from a rare disease company into a preeminent specialty care business, deeply rooted in science.
“I am confident in Bill’s experience and leadership to build on this strong foundation as we chart the next chapter for Sanofi Genzyme, which has become a real growth driver for Sanofi.”
Sibold will succeed David Meeker, who will leave the company at the end of June.